Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Gilead Sciences’ Hong Kong unit has received conditional approval from the country’s Pharmacy and Poisons Committee for the use of Veklury (remdesivir) to treat Covid-19.
The Committee held an ad-hoc meeting to review the company’s application and speed-up the registration approval of the drug.
Under the conditional approval, Gilead has to submit additional data collected on the safety, efficacy and quality of remdesivir from ongoing clinical studies and post-marketing report to Hong Kong’s Drug Office of Department of Health.